Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis
Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis
复制标题
DOI：
10.1046/j.1365-2141.2001.03019.x
复制
发表时间：
2001-09-01
影响因子：
6.5
通讯作者：
Lister, TA
中科院分区：
文献类型：
--
作者：
Foran, JM;Norton, AJ;Lister, TA
一项对利妥昔单抗治疗B细胞非霍奇金淋巴瘤后CD 20表达的回顾性分析表明，6/25例（24%）持续骨髓（BM）浸润患者的免疫表型发生了显著变化。6例患者中有3例的B细胞均为CD 20（-）/CD 79 α（+），与CD 20表达的明显缺失一致。在其余3例病例中，BM浸润主要为（> 80%）CD 20（-）/CD 79 α（+）。前者中有2例达到临床缓解，而后者3例均未达到临床缓解。在另外三个病例中，治疗后BM浸润完全由良性或反应性CD 3（+）T细胞组成。在25例治疗后淋巴结活检中未观察到CD 20的Frank丢失。因此，免疫表型是诊断利妥昔单抗治疗后骨髓浸润的重要辅助手段。
A retrospective analysis of CD20 expression following rituximab for B-cell non-Hodgkin's lymphoma demonstrated a significant change in immunophenotype in 6/25 (24%) patients with persistent bone marrow (BM) infiltration, In three out of six patients, the B cells were uniformly CD20(-)/CD79 alpha (+), consistent with frank loss of CD20 expression. In the remaining three cases, the BM infiltrate was predominantly (> 80%) CD20(-)/CD79 alpha (+). Two of the former but none of the latter three cases achieved a clinical response. In three further cases, the posttreatment BM infiltrate was composed entirely of benign or reactive CD3(+) T cells. Frank loss of CD20 was not seen in 25 post-treatment lymph node biopsies. Immunophenotyping is therefore an important adjunct in the diagnosis of BM infiltration following rituximab.